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doi:10.1016/j.febslet.2009.06.005One of the FEBS Letters Editors that we particularly value for his
knowledge, coherence and experience, and that we willingly rely
on is Dr. Angel Nebreda, currently a group leader at the CNIO (Span-
ish National Cancer Research Center) in Madrid, Spain. Dr. Nebreda
has contributed to cutting-edge science in some of the most presti-
gious research institutes around the world, including the NIH in
Bethesda, USA, the Cancer Research-UK Laboratories in South Mim-
ms, UK, with Tim Hunt, and the EMBL in Heidelberg, Germany,
where he started his own lab. Angel Nebreda joined the FEBS Letters
Editorial Board in 2004.
Do you enjoy being an Editor for FEBS Letters?
Before joining FEBS Letters I had been an author and a reviewer,
but never an editor. Since I have been on board I have seen thankful
authors as well as angry authors, and I have dealt with thoughtful
referees, superﬁcial referees, or even vicious referees. It is an inter-
esting experience, and I learn a lot from it, which is why I do it in
the ﬁrst place.
What are your current research interests?
My group at the CNIO is called Signalling and Cell Cycle. We are
mainly interested in signal integration and transduction. We try to
understand how cells are able to elaborate responses taking into
account the cellular information that is available to them. We
mostly focus on signalling pathways that have a role in regulating
the cell cycle, and have implications in the development of cancer.
I heard that you are one of the fathers of the MAP kinase
family. . .
Fifteen years ago, when I was in Tim Hunt’s lab and in collabo-
ration with the group of Philip Cohen in Dundee, we published one
of the ﬁrst members of the p38 MAPK family [1]. It had actually
started as a side project, almost a hobby, and it then turned out
to be a key player in cell regulation, which has strong implications
in cancer. We have recently started to use mouse models to under-
stand the role of p38 MAPKs in tumourigenesis, as well as in the
regular physiology of the mouse. We have shown that p38a hased by Ea critical role in lung homeostasis, maintaining the balance be-
tween proliferation and differentiation of lung epithelial cells [2].
The knock out has immature epithelia resembling early stages of
lung tumourigenesis.
Has p38a been found mutated in human tumours?
Not really. p38a can be considered a member of the tumour
suppressor class II molecules, which are not mutated in tumours,
but can negatively regulate tumour formation. Cancer cells are
somehow able to rewire signalling pathways and exploit them to
their own advantage, for example avoiding control mechanisms
such as oxidative stress, which would lead to the apoptotic death
of the cancer cell. Understanding how cancer cells achieve the
reprogramming of the signalling pathway is a key to solve the
riddle.
Have your studies led to possible therapeutic applications?
Yes, in a way. There are many p38a inhibitors, which have been
developed by pharmaceutical companies to treat inﬂammation. In
some cancers p38a appears to have an important role, and by
inhibiting its function you might also interfere with the develop-
ment of the tumour. Although p38a is normally a tumour suppres-
sor, if this step is bypassed and the tumour takes over, then p38a
sometimes has a role in enhancing tumourigenesis. However, we
have shown that if you inhibit p38a in normal cells, you facilitate
the onset of lung tumours in mouse models [2]. Based on our re-
sults, we would suggest that smokers, who are already prone to
developing lung cancer, should not take p38a inhibitors. On the
contrary, once an individual has developed lung cancer, p38a
inhibitors might be useful to impair tumour growth.
In your opinion, how is the economical crisis affecting science?
Unfortunately, there have already been budget reductions,
although they have not been drastic so far. This year’s budget
had already been planned, but if things don’t improve it is unlikely
that the funding can stay the same for the next few years. The crisis
is affecting science just as any other activity of life.lsevier B.V. All rights reserved.
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your own country?
During my university years, in Spain, funding was very limited,
and I remember we used to wash and reuse plastic tubes in the lab.
But in the last twenty years there has been a spectacular change
and it is now possible to do competitive science at high level in a
number of Spanish research institutes. After 18 years abroad, I
was offered the opportunity to run a lab at the CNIO, which is
new and has good funding. It was an excellent opportunity to con-
tribute to Spanish science and to focus more on cancer research.
I also felt it was time that my children, who were born abroad
and had always lived in foreign countries, had the opportunity to
discover their origins. I remember one day in Germany, I was wait-
ing at the bus stop with my eight-year-old daughter, when a wo-
man approached her and asked where she was from. My
daughter turned to me and asked: ‘‘Where am I from?” It was time
to go back home.
If you weren’t a scientist, what would you be?
I would have liked to be a football player, but to be honest I
don’t think I would have many chances to succeed. In retrospect,
I would have enjoyed being a medical doctor, mostly for the oppor-tunity to help people in a direct and practical way. However, being
a scientist is still what appeals to me more than any other
profession.
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